Please login to the form below

Not currently logged in
Email:
Password:

Spirogen

This page shows the latest Spirogen news and features for those working in and with pharma, biotech and healthcare.

MedImmune partners with US National Cancer Institute

MedImmune partners with US National Cancer Institute

AZ boosted its pipeline in thsi area with the $440m acquisition of Spirogen.

Latest news

  • MPs grill Read over Pfizer's commitments to UK MPs grill Read over Pfizer's commitments to UK

    with a move away from commercial-led megamergers and a shift towards small- and mid-scale, science-led acquisitions such as its recent purchase of Spirogen.

  • Soriot says pipeline will speed recovery at AZ Soriot says pipeline will speed recovery at AZ

    Last year it bought respiratory company Pearl Therapeutics in a $1.15bn deal as well as biopharma companies AlphaCore Pharma, Spirogen, Amplimmune and Omthera Pharmaceuticals.

  • 2013 - biotech boomed 2013 - biotech boomed

    AZ's 2013 deal-making spree also saw it acquire Amplimmune, a Maryland, US-based biotech with a number of early-stage cancer projects, and UK firm Spirogen, which develops ... Financial details of the AlphaCore deal were not released, but AZ's

  • AZ said to be eyeing Forest takeover bid AZ said to be eyeing Forest takeover bid

    Last month the company agreed to pay $440m to buy antibody-drug conjugate (ADC) specialist Spirogen, while in August it bought cancer company Amplimmune in a deal valued at up to

  • Incubating biotech’s future Incubating biotech’s future

    the economic downturn, as well as Biomoti, Mediwise, Duvas Technologies, Spirogen and The Specialist Pharmacy.

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Pharma deals during October 2013 Pharma deals during October 2013

    Auven's portfolio of companies includes Resolvyx, Kiacta, Kolitan and Sprout Pharmaceuticals, as well as Spirogen and ADC Therapeutics. . ... The Spirogen/Auven Therapeutics deal with MedImmune discussed above re-confirms that ADC technology is

  • Deal Watch table for October 2013 Deal Watch table for October 2013

    730. Spirogen / MedImmune. Acquisition. ADC technology - oncology (lead asset in phase II).

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics